Gradientech receives European patent for antibiotic susceptibility testing

Swedish health technology company Gradientech has announced the grant of a European patent by the European Patent Office (EPO) for its antibiotic susceptibility testing (AST) system. The patent covers the company's technology for determining how susceptible bacteria are to different antibiotics.

Gradientech's system aims to provide a significantly faster method for identifying effective antibiotic treatments compared to traditional laboratory methods, which can often take several days. This speed is crucial for initiating appropriate patient care promptly in cases of bacterial infections.

Recent company activities include the further development and commercialization of its QuickMIC system, alongside participation in relevant scientific conferences and collaborations with healthcare institutions. Gradientech has reported on clinical studies and distribution agreements in Europe.

The company's focus remains on addressing the challenge of antibiotic resistance. Securing patent protection in key markets like Europe is a significant step in establishing its technology and contributing to improved patient outcomes in infectious disease management.